DexCom, Inc. (DXCM)
POSITIVEFundamental
77
Kurs
$89.40
Marktkapitalisierung
$34.36B
Teil 1 · Was das Unternehmen wert ist
Übersicht
DexCom makes continuous glucose monitors — small wearable sensors that track blood sugar every few minutes and send readings to a phone or an insulin pump, replacing the finger-prick test that diabetics used for decades. Its main product line is the G7 sensor and its Stelo variant for people not on insulin. It sells almost entirely one category of medical device, in two markets — the United States and abroad — rather than a diversified portfolio.
Wie das Geld verdient wird
DexCom earns revenue mainly by selling a recurring supply: sensors that must be replaced every 10-15 days and transmitters replaced less often, so once a patient starts, the ongoing sensor purchases resemble a subscription even though they are billed per shipment. Sales flow largely through distributors and pharmacies who bill insurers or government payers on the patient's behalf, and reimbursement approval from insurance or Medicare, not the patient's own spending, determines whether a sale happens at all.
Umsatz nach Segment
Sales to US patients, mostly billed through insurance or Medicare via distributors and pharmacies — where DexCom has been established longest.
Sales outside the US, growing faster than the domestic market as DexCom expands reimbursement coverage abroad.
Wettbewerbsvorteil
Wechselkosten · SchmalPatients build months or years of glucose history and habits around one sensor and app, and DexCom's sensors are integrated with several insulin pump makers' systems, so switching means a new prescription, a new pump pairing and relearning the device. That keeps most patients in place once started, but Abbott's FreeStyle Libre competes closely on price and features, so the advantage is not decisive.
Was die Nachfrage antreibt
DefensivDemand is driven by the number of people with diabetes who are prescribed a continuous monitor, a population that grows steadily regardless of the economic cycle, plus the pace at which insurers extend reimbursement to more patient groups. Growth can still slow when a competitor cuts price or when a payer tightens coverage rules, but the underlying need for glucose monitoring does not disappear in a downturn.
Wichtigste Risiken
- Reliance on a small number of distributors — Most sales are routed through a handful of pharmacy and medical-supply distributors rather than direct to patients; losing one or a change in its terms would disrupt a large share of shipments.
- Single-source manufacturing and FDA oversight — Some components come from single-source suppliers, and DexCom's factories and any product change remain subject to FDA inspection and approval; a failed inspection or an unauthorized change can halt shipments.
- Reimbursement decisions by insurers and Medicare — A sale generally only happens if an insurer or government payer agrees to reimburse the device; a coverage cut or a slower approval process for new patient groups directly reduces revenue.
- Competition from Abbott and other monitor makers — Abbott's FreeStyle Libre and other continuous glucose monitors compete directly on price, accuracy and insurer coverage, and a lost contract with a major payer can shift patients to a rival overnight.
Kundenkonzentration
DexCom sells through a small number of large distributors and pharmacy partners rather than directly to most patients; the company has not disclosed a current percentage for its largest partners, but historically a handful of them each represented a meaningful share of revenue.
Die Argumente dafür
Buyers argue that the diabetic population needing continuous monitoring keeps growing, that recurring sensor purchases behave like a subscription once a patient is on the device, and that expanding international reimbursement gives DexCom years of runway outside its largest market.
Die Argumente dagegen
Sellers fear that Abbott's Libre competes aggressively on price, that reimbursement decisions outside the company's control can cut off whole patient groups, and that dependence on a handful of distributors and single-source suppliers leaves little room for a manufacturing or regulatory setback.
Written by the editors, published on 18. August 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$4.97B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$1000M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$1.08B
Gesamtes Eigenkapital
$2.75B
Gesamtverbindlichkeiten
$3.59B
Current Ratio
1.73
Zinsdeckungsgrad
75.94
Schulden/EBITDA
1.20
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$64.89
Aktueller Kurs
$89.40
Sicherheitsmarge
-37.8%
Innerer-Wert-Spanne
$42.18 - $87.60
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
36.13
ROE
30.5%
P/B-Verhältnis
13.11
P/FCF
24.46
Bruttomarge
62.5%
ROIC
22.0%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
22.0%
WACC
12.2%
ROIC − WACC
+9.8 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamentalanalyse-Kriterien
Bestanden (22)
- EPS shows upward trend
- Price CAGR 19.99%
- ROIC 22.0%
- Gross Margin 62.5%
- P/FCF 24.46
- Debt/Equity ratio
- Operating Margin 22.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 36.2%
- Revenue Growth 5Y 19.3%
- Analyst Consensus 86% Buy
- Earnings Surprise avg 12.9%
- Earnings Quality (OCF/NI) 1.75
- Share Dilution -1.4%
- Net Margin Trend 20.1% vs 13.3%
- Piotroski F-Score 8/9
Nicht bestanden (4)
- P/B Ratio 13.11
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 3.62
Nicht verfügbar (1)
- Dividend Payout NaN%
Piotroski F-Score
Starke finanzielle Gesundheit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Kevin Ronald Sayer | Executive Chairman of the Board | 67 |
| Mr. Jacob Steven Leach | President, CEO & Director | 47 |
| Mr. Jereme M. Sylvain CPA | Executive VP, CFO & Chief Accounting Officer | 45 |
| Mr. Michael Jon Brown J.D. | Executive VP, Chief Legal & Compliance Officer | 55 |
| Ms. Sadie M. Stern | Executive VP, Chief People & Culture Officer | 50 |
| Mr. Jon Coleman | Executive VP & Chief Commercial Officer | 61 |
| Mr. Peter Simpson | Executive VP & CTO | - |
| Mr. Sean Christensen | Vice President of Finance and Investor Relations | - |
| Mr. Matthew Dolan | Executive Vice President of Strategy & Corporate Development | 44 |
| Keri Leone | Senior Director of Global Medical Science & Education | - |
Prüfungsrisiko
2
Vorstandsrisiko
7
Vergütungsrisiko
5
Aktionärsrechterisiko
6
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for DXCM, sourced from Markets Gazette.
- 5/22/2026POSITIVEHere's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years
An analysis of DexCom Inc. stock reveals a substantial return for long-term investors over the past 15 years. While specific figures are not provided in this snippet, the title implies significant capital appreciation, likely driven by the company's innovative continuous glucose monitoring (CGM) devices. For investors, this historical performance suggests strong market positioning and successful product adoption in the diabetes technology sector, potentially indicating continued growth prospects. The article likely details the key milestones and market factors contributing to this impressive investor return.
- 5/15/2026POSITIVEDexcom’s Bet Beyond Diabetes
Dexcom CEO Jake Leach highlighted the expanding market for continuous glucose monitors (CGMs) beyond diabetes management during a Bloomberg interview. He stated that GLP-1 drug approvals are accelerating CGM adoption and reaffirmed the company's robust growth projections. Leach also detailed Dexcom's strategic expansion into the broader metabolic health and wellness sector. This diversification strategy, coupled with the positive impact of GLP-1 drugs, suggests a significant untapped market potential, positioning Dexcom for sustained revenue growth and market share expansion.
- 3/2/2026POSITIVEHere's How Much You Would Have Made Owning DexCom Stock In The Last 10 Years
DexCom Inc.'s historical stock performance over the past ten years has proven exceptionally profitable for investors. While specific return details were not disclosed in this update, the headline strongly implies that the company, a leader in diabetes management technologies, has generated substantial gains. This information is critical for investors assessing a company's long-term growth potential and stability within the healthcare sector. DexCom's ability to sustain a positive growth trajectory for a decade underscores the strength of its innovation and the increasing demand for its continuous glucose monitoring systems, positioning it as an attractive option for growth-oriented portfolios.
- 2/25/2026POSITIVEGot $10,000? I Think DexCom Stock Could Be a Quiet Winner of the GLP‑1 Wars
DexCom Inc. emerges as a compelling investment opportunity, positioned as a potential 'quiet winner' amidst the competitive landscape of GLP-1 medications. While the focus often remains on pharmaceutical giants, DexCom's innovative medical devices, particularly its continuous glucose monitoring (CGM) systems, are crucial for managing conditions like diabetes, which are intrinsically linked to the GLP-1 drug market. The increasing adoption of GLP-1s could inadvertently boost demand for DexCom's monitoring solutions, as patients and healthcare providers seek better ways to track health outcomes. This synergy presents a robust case for investors looking beyond direct drug manufacturers, highlighting DexCom's strategic importance in the evolving healthcare sector.
via Markets Gazette